Systemic psoriasis therapy - The next step. Adalimumab;Systemische psoriasistherapie - Der nächste schritt. Adalimumab

Hautarzt

Volumn 58, Issue 6, 2007, Pages 515-524

  Wozel, G ^a   Sticherling, M ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Adalimumab (Humira ); Dermatological indication; Psoriasis vulgaris; Psoriatic arthritis; TNF TNF blocking agents

Indexed keywords

ADALIMUMAB; ANTIPSORIASIS AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDICATION; HUMAN; IMMUNOTHERAPY; INFECTION; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC THERAPY; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CLINICAL TRIALS; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 34250351329     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-007-1338-5     Document Type: Review

References (50)

1. Aberra FN (2006) To be or not to be: Infliximab during pregnancy? Inflamm Bowel Dis 12: 76-78
2. (2005) Adalimumab. In: McEvoy GK, Snow EK et al. (eds) AHFS Drug Information, American Society of Health-System Pharmacists. Bethesda, pp 3620-2623
3. Baecklund E, Ekborn A, Sparén P et al. (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Br Med J 317: 180-181
4. Blum R, Lebwohl M, Wong V et al. (2005) Durability of treatment response in patients with moderate to severe psoriasis following withdrawal from or a dose reduction in adalimumab therapy. J Am Acad Dermatol 52 [Suppl]: P2737
5. Bongartz T, Härle P, Friedrich S et al. (2005) Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab. Arthritis Rheum 52: 280-282
6. Bongartz T, Sutton AJ, Sweeting MJ et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 295: 2275-2285
7. Bonish BK, Patel T, Hoffman R et al. (2005) STAT3 is activated in psoriatic plaques and rapidly reduced following treatment with anti-TNFα monoclonal antibody, adalimumab. The 66th Annual Meeting of the Society for Investigative Dermatology, St. Louis, USA, May 04-07
8. Chew AL, Bennett A, Smith CH et al. (2004) Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol 151: 492-496
9. Cush JJ (2005) Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis [Suppl 4] 64: 18-23
10. Broeder AA den, Wanten GJA, Riel PLCM van et al. (1998) The effect of D2E7, a new human anti-TNFα monoclonal antibody, on the oxidative burst of PMN in patients with RA. Arthritis Rheum 41: S57
11. Gannes GC de, Ghoreishi M, Pope J et al. (2007) Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 143: 223-231
12. DeRuiter J, Riley TN (2003) How can Adalimumab (Humira®) be used to treat rheumatoid arthritis? Pharmacist 28: online publiziert
13. Estrach C, Mpofu S, Moots RJ (2003) Efficacy and safety of infliximab and adalimumab in Behcet's syndrome. 67th Annual Scientific Meeting of the American College of Rheumatology, Orlando, Florida, October 23-28
14. Fiorentino DF (2007) The Yin and Yang of TNF-α inhibition. Arch Dermatol 143: 233-236
15. Foeldvari I, Kümmerle-Deschner J, Horneff G et al. (2005) Results of a multinational survey regarding the use of tumor necrosis factor alfa blocker in the treatment of juvenile idiopathic arthritis associated severe uveitis. EULAR, Wien. http://www.eular.org
16. Gordon KB, Bonish BK, Patel T et al. (2005) The tumour necrosis factor-α inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 153: 945-953
17. Heffernan MP, Smith DI (2006) Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 142: 17-19
18. Humira® 40 mg Injektionslösung in Fertigspritze. Fachinformation Juni 2006
19. Humira® Produktmonographie Oktober 2003
20. Katz JA (2004) Pregnancy and inflammatory bowel disease. Curr Opin Gastroenterol 20: 328-332
21. Kempeni J (1999) Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7. Ann Rheum Dis [Suppl I] 58: 170-172
22. Kohno T, Stevens S, Louie J (2005) Adalimumab and infliximab bind to Fc-receptor and C1q and generate immunoprecipitation: a different mechanism from etanercept. J Am Acad Dermatol 52 [Suppl]: P400
23. Langley R, Leonardi C, Toth D, Hoffman R (2005) Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis. AAD, Annual Scientific Meeting, San Diego, California, November 12-17
24. Mahadevan U, Kane S, Sandborn WJ et al. (2005) Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 21: 733-738
25. Mease PJ (2005) Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Expert Opin Biol Ther 5: 1491-1504
26. Mease PJ, Gladman DD, Ritchlin TST et al. (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum 52: 3279-3289
27. Mease P, Gladman D, Richtlin C et al. (2005) Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT. ACR, Annual Scientific Meeting, San Diego, California, November 12-17
28. Menter MA, Gordon KB, Leonardi C et al. (2005) Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis. AAD, Annual Scientific Meeting, San Diego, California, November 12-17
29. Patel T, Gordon KB (2004) Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther 17: 7442-7431
30. Patel T, Leonardi C, Kang S, Gordon K (2005) Treatment with adalimumab induces rapid normalization of epidermal keratinocytes in psoriasis patients. J Am Acad Dermatol 52 [Suppl]: P2816
31. Robert Koch Institut (2005) Epidemiologisches Bulletin Hinweise zu Impfungen für Patienten mit Immundefizienz. Nr. 39
32. Robert Koch Institut (2005) Epidemiologisches Bulletin Neuerungen in den aktuellen Impfempfehlungen der STIKO. Nr. 31
33. Santora LC, Kaymakcalan Z, Sakorafas P et al. (2001) Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography and BIAcore. Anal Biochem 299: 119-129
34. Scheinfeld N (2005) Adalimumab: a review of side effects. Expert Opin Drug Saf 4: 637-641
35. Scheinfeld N (2003) Adalimumab (Humira): a review. J Drug Dermatol 2: 375-377
36. Schiff MH, Burmester GR, Kent JM et al. (2006) Safety analyses of adalimumab (Humira®) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis; published online
37. Schmitt J, Wozel G (2005) The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210: 194-199
38. Schreiber St (2006) Ein erhöhtes Krebsrisiko ist nicht hinreichend belegt. Meta-Analyse zur Therapie der rheumatoiden Arthritis mit Anti-TNF-Präparaten weist methodische Schwächen auf. Dtsch Arztebl 103: 1310
39. Sfikakis PP, Iliopoulos A, Elezoglou A et al. (2005) Psoriasis induced by anti-tumor necrosis factor therapy - a paradoxical adverse reaction. Arthritis Rheum 52: 2513-2518
40. Sladden MJ, Mortimer NJ, Hutchinson PE (2005) Extensive plaque psoriasis successfully treated with adalimumab (Humira®). Br J Dermatol 152: 1062-1094
41. Tjioe M, Gerritsen MJP, Den Broder AA et al. (2003) Adalimumab, a fully human anti-TNF-α monoclonal antibody, treatment does not influence experimental UV response in the skin of rheumatoid arthritis patients. Exp Dermatol 12: 460-465
42. Ubriani R, Voorhees AS van (2007) Onset of psoriasis during treatment with TNFα antagonists: a report of 3 cases. Arch Dermatol 143: 270-271
43. Vaszquez-Cobian LB, Flynn T, Agle LMA et al. (2003) Treatment of resistant uveitis in children with adalimumab. 67th Annual Scientific Meeting of the American College of Rheumatology, Orlando, Florida, October 23-28
44. Vesga L, Terdiman JP, Mahadevan U (2005) Adalimumab use in pregnancy. Gut 54: 890
45. Vitéz L, Wozel G (2006) Adalimumab: complete clearing of skin lesions in a severe psoriatic arthritis patient. International Proceedings. 15th EADV Congress. Rhodos, 4.-8. Oktober, pp 785-788
46. Wallace K, Gordon K, Langley R et al. (2005) Dermatologic quality of life in patients with moderate to severe plaque psoriasis receiving 48 weeks of adalimumab therapy. J Am Acad Dermatol 52 [Suppl]: P2734
47. Wallace KL, Langley R, Bissonnette R et al. (2005) Quality of life in patients with psoriatic arthritis treated with adalimumab: subanalysis of studies in moderate to severe psoriasis. J Am Acad Dermatol 52 [Suppl]: P2783
48. Weisman MH, Moreland LW, Furst DE et al. (2003) Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25: 1700-1721
49. Wozel G, Jahn S (2006) Biologics in der Dermatologie, 2. Aufl. UNI-MED Verlag AG, Bremen London Boston
50. Ziakas PD, Giannouli S, Tzioufas AG, Voulgarelis M (2003) Lymphoma development in a patient receiving anti-TNF therapy. Haematologica 88: ECR25